Valeo Pharma Inc. announced that it has received notice of a positive recommendation by Quebec's Institut national d'excellence en santé et en services sociaux to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), RedescaTM and RedescaTM HP, on the list of medications covered by the Régie de l'assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.